Cypress Pharmaceutical, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company's abbreviated new drug application (ANDA) for Levetiracetam Oral Solution, 100 mg/mL.
Levetiracetam Oral Solution, 100 mg/mL is the AB-rated bioequivalent generic to UCB Pharma's Keppra® Oral Solution, 100 mg/mL.
Cypress' Levetiracetam Oral Solution, 100 mg/mL will be available through all the national drug wholesalers and chain drug stores and will begin shipping immediately.
About Cypress Pharmaceutical, Inc.
Cypress Pharmaceutical, Inc., founded in 1993, is a specialty pharmaceutical company that develops, markets and distributes generic prescription pharmaceutical products to leading national pharmaceutical wholesalers, chain drug stores, distributors, and other retail merchandisers. Cypress has an aggressive product development pipeline including new drug applications (NDAs) and abbreviated new drug applications (ANDAs) with over 30 products in various stages of development.